On the final trading day of July 2026, Angelalign (6699.HK) released a positive profit alert: for the first half of 2026, the company expects total revenue of approximately $2.29 billion to $2.31 billion, representing a year-on-year increase of 41.9% to 43.1%. Net profit is projected to reach $24 million to $25.4 million, surging 69.0% to 78.9% compared to the same period last year. The total number of clear aligner cases reached approximately 316,600, a 40.2% increase from the prior year. On August 3, the first trading day after the announcement, Angelalign shares opened 8.2% higher, hitting an intraday high of HKD 97, with gains exceeding 21% at one point, before closing at HKD 94.25, up 17.96%. The company's market capitalization rebounded to around HKD 16 billion. "China's first invisible orthodontics stock" is regaining the trust of capital markets.

Breaking Down the Profit Alert: Overseas Expansion Accelerates, Domestic Market Recovers

The most striking aspect of this profit alert is the simultaneous high-speed growth across global markets. In terms of case numbers, worldwide clear aligner cases totaled approximately 316,600 in the first half of 2026, a 40.2% increase year-on-year. Among these, overseas markets contributed about 168,000 cases, up 43.3%, while the Chinese mainland market accounted for approximately 148,600 cases, growing about 36.8%. For the first time, overseas markets not only surpassed the domestic market in scale but also demonstrated faster growth, becoming the group's primary growth engine. Looking back at 2025, Angelalign's full-year case count reached 532,400, a 48% increase, with 276,200 cases domestically (+26%) and 256,200 cases overseas (+82%). Overseas revenue reached $163 million (+102%), with its share of total revenue climbing from 30% in 2024 to 44%. The first-half 2026 data indicates this trend is accelerating: overseas half-year cases of 168,000 already exceed the full-year overseas case count of approximately 120,000 in 2024, signaling that the scale effects of the internationalization strategy are being released intensively. Domestically, Angelalign's position remains solid. According to Minet data, China's total number of bracketless clear aligner cases reached 731,600 in 2025, with Angelalign ranking first with 276,200 cases and a 37.75% market share. Zhengya Dental followed closely with 28.26%, while Invisalign fell to 24.82%. The industry has evolved from a "duopoly" to a "three-way standoff," but the two domestic players together have captured 66% of the market. In its announcement, Angelalign attributed the performance improvement to three factors: increased market preference for products and services with stable clinical efficacy; the initial release of operating leverage from the global direct sales network; and an open management culture that integrates multinational technical talent, accelerating product and service innovation.

Remaining Concerns: Patent Litigation and Intensifying Competition

However, the market is not without concerns. Patent litigation remains a sword of Damocles hanging over the company. In August 2025, Align Technology, Invisalign's parent company, filed patent infringement lawsuits against Angelalign in the United States, Europe, and China. In May 2026, the Unified Patent Court in Europe rejected Align Technology's request for a preliminary injunction against Angelalign's A7 premolar extraction solution. But in February 2026, the Düsseldorf Unified Patent Court in Germany issued a preliminary injunction against specific software features, requiring Angelalign to suspend the use of certain modules within its automatic update function in some European countries. The final outcome of the litigation remains a critical variable affecting valuation. The competitive landscape is also evolving. Zhengya Dental is preparing for an IPO on the ChiNext board, aiming to raise 901 million yuan. If successfully listed, industry competition intensity could further increase. Additionally, potential risks from centralized procurement of clear aligners and geopolitical factors are listed by institutions as risks requiring ongoing monitoring.

Conclusion

Angelalign's profit alert is not just a stellar performance forecast but also a periodic validation of the company's strategic transformation over the past few years. From the peak of its 2021 IPO, through the profit pressure and share price halving from 2023 to 2024 due to overseas investment, to the current harvesting phase of its overseas business and return to high-profit growth, Angelalign's capital market trajectory reflects the typical path of Chinese consumer healthcare companies going global: heavy upfront investment with limited market patience, but once scale effects kick in, valuation recovery often comes swiftly. The answers to three questions—whether overseas markets can sustain high growth, whether patent litigation can be resolved smoothly, and whether domestic lower-tier market penetration can deepen—will determine whether Angelalign can transition from a "profit surprise rebound" to a "trend reversal."